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Abstract
Background
There is a clinical need for new therapeutic products against Herpes simplex virus (HSV).
The pomegranate, fruit of the tree Punica granatum L, has since ancient times been linked
to activity against infection. This work probed the activity of pomegranate rind extract (PRE)
and co-administered zinc (II) ions.
Materials and methods
PRE was used in conjunction with zinc (II) salts to challenge HSV-1 and aciclovir-resistant
HSV in terms of virucidal plaque assay reduction and antiviral activities in epithelial Vero
host cells. Cytotoxicity was determined by the MTS assay using a commercial kit.
Results
Zinc sulphate, zinc citrate, zinc stearate and zinc gluconate demonstrated similar potenti-
ated virucidal activity with PRE against HSV-1 by up to 4-fold. A generally parabolic relation-
ship was observed when HSV-1 was challenged with PRE and varying concentrations of
ZnSO4, with a maximum potentiation factor of 5.5. Punicalagin had 8-fold greater virucidal
activity than an equivalent mass of PRE. However, antiviral data showed that punicalagin
had significantly lower antiviral activity compared to the activity of PRE (EC50 = 0.56 μg
mL-1) a value comparable to aciclovir (EC50 = 0.18 μg mL-1); however, PRE also demon-
strated potency against aciclovir-resistant HSV (EC50 = 0.02 μg mL-1), whereas aciclovir
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showed no activity. Antiviral action of PRE was not influenced by ZnSO4. No cytotoxicity
was detected with any test solution.
Conclusions
The potentiated virucidal activity of PRE by coadministered zinc (II) has potential as a multi-
action novel topical therapeutic agent against HSV infections, such as coldsores.
Introduction
The Herpes simplex virus is a member of the Herpes viridae family and infects a high propor-
tion of the populace, causing a range of diseases from mild uncomplicated mucocutaneous (eg
coldsores) to more serious infections, such as keratitis. HSV-1 is the causal agent of coldsores
and encephalitis, while HSV-2 is normally associated with anogenital infections, which can
transfer from mothers to neonates. The current gold standard treatment for HSV infections is
aciclovir, a guanine analogue antiviral drug, which has a virustatic mode of action and is more
effective in early-stage coldsores. Coupled with the emergence of Herpes strains that are resis-
tant to nucleoside analogues, including aciclovir [1], there exists an urgent clinical need for
new and more effective treatments for HSV infections, ideally ones that exert virucidal activity.
This work concerns the development of such a new therapeutic system based upon the potenti-
ated activity against HSV of pomegranate rind extract (PRE). For the purposes of this work the
terminology; virucidal, pertains to the effect of a chemical or agent that prevent infection due
to physical changes to the virus effectively ‘killing’ them and virustatic, pertaining to the inter-
ference of the viral life cycle and biological processes that preventing replication of the virus.
The pomegranate, fruit from the Punica granatum L. tree, is part of the punicaceae family
native to the Middle East and has been used since antiquity as a remedy for a range of clinical
conditions. The juice, seed, peel and rind of the pomegranate contain a wide range of phyto-
chemicals [2] and there has been a substantial amount of research conducted upon different
pomegranate components and chemical extracts. The major concentration of phytochemicals
is within the pericarp and these include tannins, anthocyanidins such as delphinidin, cyanidin
and pelargonidin, proanthocyananidins and various flavonoids, with significant antioxidant
activity demonstrated in various in vitro models [3]; the antimicrobial effects of hydrolysable
tannins was recently reviewed [4]. Antibacterial bioactivity of PRE has been observed using
fractions extracted with acetone and methanol against both Gram-positive and Gram-negative
bacteria. Complete growth inhibition of B. cereus, B. subtilis, B. coagulens, S. aureus, E. coli and
P. aeruginosa was shown at 300 ppm [5]. The inhibition of α-glucosidase and human leukocyte
elastase activity by PRE has been reported [6]—this action was claimed to impede viral attach-
ment and penetration via disruption of the glycosylation of viral glycoproteins. Pomegranate
juice extracts have antiviral effects against human immunodeficiency virus (HIV); the mecha-
nism of action appeared to inhibit the binding of the HIV-1 envelope glycoprotein gp 120, pre-
venting the interaction of HIV-1 with the CD4 receptor, and thus reducing the infectivity of
the virus [7].
The phytochemicals of particular interest within PRE are the hydrolysable tannins: punica-
lin, gallic and ellagic acid esters of glucose and most notably punicalagin [8]. Punicalagin (MW
1084.7) and its major degradation product ellagic acid which are thought to be the major bio-
active phytochemicals present in PRE [9]. Punicalagin is a large polyphenolic compound with
a molecular mass of 1084.7 and is the most abundant tannin in PRE, constituting 80–85% w/w
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of the total. The structure consists of two subunits, punicalin and ellagic acid, linked via a hex-
ose bridge and the overall molecule exists in one of 2 isomeric forms (anomers)–punicalagin α
and β in a ratio of approximately 1:2 respectively. It was shown that punicalagin targeted and
inactivated HSV-1 viral particles and could prevent binding (attachment), penetration, and
cell-to-cell spread, as well as secondary infection [10]. Punicalagin was further reported to be
effective in abrogating infection by human cytomegalovirus (HCMV), hepatitis C virus
(HCV), dengue virus (DENV), measles virus (MV), and respiratory syncytial virus (RSV),
at μM concentrations and in dose-dependent manners without significant cytotoxicity [11];
although the effect of punicalagin was not investigated as a potential virucide.
Antimicrobial or microbicidal potentiation can be described as significantly increased
activity of an agent in the presence of a second, generally inactive agent. The scope for potenti-
ated virucidal activity of PRE was revealed in the combination of PRE and ferrous sulphate
(FeSO4) in a pH4.5 buffer [12]. The combination of PRE and FeSO4 was reported to produce a
potent eleven-log reduction in the plaque forming ability of Pseudomonas aeruginosa and
Escherichia coli phages [13] within two minutes of application of an aqueous mixture at room
temperature [12]. Significant and detrimental damage was observed to the head and tail
regions as well as to their overall integrity. Despite its demonstrable potency, the virucidal
action of PRE and FeSO4 is fugitive and rapidly diminishes once the co-administration has
taken place; which coincides with a blackening of the solution and has been attributed to oxi-
dation of the ferrous ion to ferric ion, possibly involving a Fenton reduction mechanism [14].
Consequently our attention turned to examining the effect of zinc (Zn II) as an alternative
potentiating/synergizing agent as it is relatively resistant to further changes in oxidation state,
is colourless and has been reported as possessing innate virucidal activity [15, 16] including
against HSV [17, 18]. In the current work we examined both the potentiated virucidal and
anti-viral activities of simultaneous PRE and Zn (II) or punicalagin and Zn (II) challenge
against HSV-1 and aciclovir-resistant HSV; cytotoxicity was determined using a commercial
test kit.
Materials and methods
Materials
Pomegranates, obtained from a local supermarket, were of Spanish origin. Punicalagin (98%),
ellagic acid (95%), zinc gluconate, zinc citrate, zinc oxide, zinc iodide, zinc nitrate and zinc
stearate were purchased from Sigma-Aldrich, Gillingham, UK. Zinc sulphate (ZnSO4), Dulbec-
co’s Modified Eagle Medium (DMEM), crystal violet, potassium hydrogen phthalate were pur-
chased from Fisher Scientific (Loughborough, UK). HSV-1 17+ (NCPV00618), HSV-2 HG52
(NCPV00151), HSV-2 132349 ACV-res (NCPV00183) and Vero (green monkey kidney epithe-
lial) cells (ATCC-CCL81) were obtained from the European Collection of Authenticated Cell
Cultures (ECACC) (Salisbury, UK). The CellTiter 96 AQueous One Solution Cell Proliferation
Assay (MTS) kit was obtained from Promega, Southampton, UK.
Preparation of pomegranate rind extract (PRE)
Six fresh pomegranates were peeled and the rinds cut into thin strips approximately 2 cm in
length then blended in deionised H2O (25% w/v) before being boiled for approximately 10
min. The crude suspension was then centrifuged at 10,400 x g at 4˚C for 30 min using a Beck-
man Coulter Avanti J25 Ultracentrifuge, before being vacuum filtered through a 0.45μm nylon
membrane filter (Merck Millipore Ltd, Cork, Ireland). The solution was then freeze-dried,
occluded from light and stored at -20˚C until required. The PRE was reconstituted by adding 2
mg to 10 mL of pH 4.5 phthalate buffer and sonicated for 10 min at 50–60 Hz and, once fully
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dissolved, sterilized by filtering through a 0.45μm Millex-FG syringe driven filter. The punicala-
gin concentration was analysed by HPLC and comprised 20% w/w of the freeze-dried material.
Herpes virus stock generation
Viral stocks were grown in Vero cells (ATCC-CCL81). A T75 of vero cells was infected with
the respective herpes virus from a titered stock at a multiplicity of infection of 0.01 and incu-
bated until 50% of cells were losing adherence in the bottle, usually at day 3–4 post-infection.
Cells and supernatant were collected, cells removed by low speed centrifugation, and the cell
free supernatant stored at -70˚C in aliquots of 1 mL. The titer of the stock was determined by
plaque assay.
Cell culture and virucidal plaque reduction assay
Vero cells were cultivated in DMEM and incubated at 37˚C under 5% CO2 in an incubator. Cells
were seeded at 5 x 105 cells per well in a 24 well plate, 24 h prior to plaque assay. Virucidal activity
was determined as log reduction. A virus suspension (106 pfu/mL) was incubated with candidate
virucidal test substance (30 min), prior to endpoint dilution (eg tenfold) and infection of a cell
culture monolayer in a number of different wells of the same size to establish the titer. This was
performed using a 24-well plate (24 WP) and each virion resulted in a localized area of infection
known as a plaque, from which the number of plaque forming units (pfu) was quantified follow-
ing crystal violet staining. Table 1 summarises the concentrations and combinations representing
the challenges in the plaque reduction assay. Obtaining a direct comparison with punicalagin
proved problematic due to the extremely low aqueous solubility of ellagic acid, therefore an alter-
native solvent was needed in which both species were soluble, and brief examination experiments
showed that 10% dimethyl sulfoxide (DMSO) in deionised H2O was suitable.
Antiviral plaque assay
Most topical treatments for skin viral infections are based upon an antiviral mechanism,
where the active compound inhibits viral replication. A plaque assay was used to assess the
Table 1. Zinc salt/tannin combinations used in virucidal assays.
Zinc compound Tannin
Zinc oxide <0.00001M ± PRE 0.05 mg mL-1
Zinc nitrate 0.0005M ± PRE 0.05 mg mL-1
Zinc citrate 0.0005M ± PRE 0.05 mg mL-1
Zinc iodide 0.0005M ± PRE 0.05 mg mL-1
Zinc stearate 0.0005M ± PRE 0.05 mg mL-1
Zinc gluconate 0.0005M ± PRE 0.05 mg mL-1
ZnSO4 0.5M (143.77 mg mL-1) ± PRE 0.05 mg mL-1 or Punicalagin 0.01 mg mL-1
0.1M (28.75 mg mL-1)
0.05M (14.37 mg mL-1)
0.01M (2.88 mg mL-1)
0.005M (1.44 mg mL-1)
0.001M (0.29 mg mL-1)
0.0005M (0.14 mg mL-1)
No addition PRE 0.05 and 0.01 mg mL-1
No addition Punicalagin 0.05 and 0.01 mg mL-1 (46.13 and 9.23 μM)
No addition Ellagic acid 0.3 mg mL-1 (1 mM)
https://doi.org/10.1371/journal.pone.0179291.t001
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antiviral activity of the test compounds by quantifying infectious viruses. Antiviral activity was
determined by the application of the test antiviral compound (pretreatment)/ challenge and
then virus (after an incubation period) to confluent Vero cells in a 24WP. Preincubation of
cells with the test compound followed by addition of the virus without rinsing away the com-
pound remaining in the media, would be reflective of an in situ scenario within the skin. Each
pure test substance was analysed in 5 different concentrations i.e. 100 μM, 50 μM, 10 μM,
5 μM and 1 μM and a control, with each dilution replicated in 4 wells; for PRE the concentra-
tions were given in μg mL-1 as it has no definable molecular weight. Medium was removed
under vacuum from the first row of four cells and 400 μL of test substance was applied. This
was repeated until all medium was removed and replaced. Once the last well was filled the time
was noted, and the plates incubated for 30 min to allow for any cellular absorption or reaction.
After the 30 min incubation period, virus suspension (average 31.09 ± 3.09 pfu/well (range
28–34, n = 6)) was added to each well, and the 24 WP rocked/swirled to ensure an even spread
of the virus. The plate was then incubated at 37˚C for 45 min with rocking/swirling every 5
min, to ensure potential viral entry into the cells. Next, 300 μL of 1.2% Avicel overlay (Sigma-
Aldrich, Gillingham, UK) was applied to each well in order to prevent infection of the mono-
layer by newly replicated virus released into the medium. The plate was incubated for three
days, then stained using crystal violet. The test substances used with this method were PRE,
ZnSO4, their combination, punicalagin, ellagic acid, phthalate buffer, alongside the established
topical antiviral drug, aciclovir. The antiviral studies did not test above 100 μM for any com-
pound. The EC50 was calculated from the sigmoid curve. Graphpad Prism 5 (GraphPad Soft-
ware Inc, California, USA) was used to analyse the data.
Cytotoxicity
Test solutions were analysed for cytotoxicity using the Cell Titer 96 AQueous assay method
(Promega, Southampton, UK) and were performed in a 96 well plate (96WP) with a known
concentration of Vero cells in each well. A density of 2.5 x 103 cells per well were used for each
plate prepared, by the trypsinisation of 80% confluent Vero cells in a T75 flask (Greiner Bio-
One, Stonehouse, UK) and reconstituted in fresh DMEM Cells were seeded into a 96WP and
incubated for 24 h at 37˚C under 5% CO2. The medium was removed by aspiration, the cells
washed three times with phosphate-buffered saline then immediately replaced with the dilu-
tions of test materials. Cells were incubated for 6, 24, 48 and 72 h. Cell Titer 96 AQueous solu-
tion was used to detect cell viability and was added to each well and the plates incubated for 1
h at 37˚C under 5% CO2. Optical density was then determined at 492 nm, with the blank sub-
tracted from each sample reading and the density mean for the control cells arbitrarily
assigned a value of 100% (n = 3).
Results and discussion
Effect of different Zinc (II) compounds on virucidal activity of PRE
Fig 1 shows a plot of log reduction for PRE, a range of zinc salts and the combination. It can be
seen that the salts alone provided very low/negligible log reductions, approx. 0.4, and across
the range there was no statistically significant difference (p> 0.05). PRE alone demonstrated
low activity with a log reduction of 0.82; however, when the PRE and zinc salt was coadminis-
tered, statistically significant (p<0.05) potentiation of the PRE was observed using zinc sul-
phate (3.88), zinc citrate (3.89) zinc stearate (3.59) and zinc gluconate (3.98). Although some
variation was apparent, the differences were not statistically significant within this group of
four salts (p> 0.05). In the case of zinc oxide, the solubility was very low and could only be
evaluated at 10−5 M, rather than 10−4 M as for the other zinc salts. Furthermore, zinc oxide is
Pomegranate potentiation by zinc
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amphoteric in nature and therefore not truly ionic, accounting for its very low aqueous solubil-
ity [19]. Virucidal activity of zinc nitrate and zinc iodide were not shown due to the high cyto-
toxicity of the mixture to the host Vero cells limiting the analysis at these concentrations; zinc
iodide also proved to be cytotoxic to the host Vero cells [20]. This was apparent visually during
the experiment by the full lysis of Vero cells and therefore lack of crystal violet staining. In a
similar manner, it can be concluded that the nitrate ion was also cytotoxic to the Vero cells.
However, the remaining salts were water-soluble ( 0.0005 M) and did not result in cell cyto-
toxicity. There were no obvious colour changes with any of the zinc salts upon the addition of
PRE, although zinc iodide was intrinsically a brown-coloured solution and remained so
throughout the experiment. These observations supported the chemical analyses carried out
demonstrating the absence of any evidence for a redox reaction involving Zn2+ [21].
Virucidal activity of PRE when combined with different levels of ZnSO4
Fig 2 shows the log reduction of HSV-1 with increasing levels of ZnSO4. A parabolic relation-
ship was observed with maximal log reduction of 4.47 ± 0.11 and 4.56 ± 0.11 after the addition
of 1.44 and 14.38 mg mL-1 of ZnSO4. After this point a decrease in virucidal activity was
observed. It can also be seen that between the two maxima a statistically significant decrease in
virucidal activity was observed at a ZnSO4 concentration of 2.88 mg mL
-1 with a log reduction
of 3.11 ± 0.57.
Fig 1. Virucidal log reduction data for the addition of PRE (0.05 mg mL-1) alone and when co-administered with a range of Zn (II) salts (0.5
mM) to HSV-1 (n = 3 ± SD). Results show the same potentiated activity for zinc sulphate, zinc citrate zinc stearate and zinc gluconate (p<0.05); thus
confirming that zinc ions were responsible for the observed potentiated virucidal activity. However, zinc nitrate and zinc iodide both showed toxicity
to the Vero host cells, whereas zinc oxide had limited solubility.
https://doi.org/10.1371/journal.pone.0179291.g001
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Virucidal activity of equal masses of punicalagin and PRE with ZnSO4
The major phytochemical present in PRE is the ellagitannin, punicalagin [22], at approxi-
mately 20%, which has been reported as possessing microbicidal activity [23]. Here the effect
of this compound on HSV was determined in isolation from the other components of PRE.
The virucidal log reduction effected by punicalagin in comparison to PRE at 0.01 and 0.05 mg
mL-1 is shown in Fig 3. The results show that the log reduction of HSV-1 pfu due to the iso-
lated punicalagin (0.05 mg mL-1) was 5.93 ± 0.35, significantly greater (x7.8) than the log
reduction due to PRE (0.05 mg mL-1) of 0.76 ± 0.66 (p< 0.05). It is important to note that a
log reduction of 5.93 is the maximal limit for the test due to the viral titer used; however, the
marked difference between the activities of PRE and punicalagin was again observed at the
lower concentration of 0.01 mg ml-1 where the differential was even greater (x46.0).
A punicalagin level 0.01 mg mL-1 is representative of the concentration of this tannin within
0.05 mg mL-1 PRE (i.e. punicalagin accounts for approximately 20% of the dry mass of PRE, as
determined by HPLC). By decreasing the concentration, the log reduction data of HSV-1 in
Fig 3 show that the virucidal log reduction due to PRE decreased from 0.76 ± 0.66 to 0.05,
and that punicalagin decreased from 5.93 to 2.4 ± 0.9. These results demonstrate the greatly
enhanced virucidal activity of punicalagin on a mass-to-mass basis relative to PRE. The viru-
cidal activity of PRE, if it is to be mainly attributed to the punicalagin content with the extract,
appears partially compromised by other components of the extract.
Fig 2. Effect of ZnSO4 concentration on the potentiated virucidal activity of PRE (0.05 mg mL-1) (n = 4 ± SD). Results show
an increase in potentiated activity up to 1.44 mg mL-1; thereafter the pattern is unpredictable, and generally decreases with higher
zinc levels.
https://doi.org/10.1371/journal.pone.0179291.g002
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Virucidal activity of PRE and ellagic acid in isolation
Punicalagin, although in greatest proportion, is by no means the only phytochemical constituent
of PRE. Here, we examined the effect of another ellagitannin, ellagic acid (EA), a direct break-
down product of the esterification of punicalagin. Fig 4 shows that the virucidal activity of EA
10% DMSO in deionised H2O was no different from blank solution (p>0.05); however, punicala-
gin showed significantly greater virucidal action than either the control or ellagic acid (p< 0.05).
Virucidal activity of punicalagin in combination with ZnSO4
Fig 5 shows the potentiation by ZnSO4 of varying concentrations on the virucidal activity of
0.01 mg mL-1 punicalagin. As previously shown in Fig 4 punicalagin had innate virucidal effect
resulting in a log reduction of 2.4 ± 0.9 (note: 0.01 mg mL-1 used here rather than 0.05 mg
mL-1). The addition of ZnSO4 (0.14 mg mL
-1) caused a large increase in potentiated virucidal
action to 4.6 ± 0.16. However, as seen in the PRE experiment (Fig 3), the addition of further
amounts of ZnSO4 caused a decrease in the virucidal activity below that of punicalagin alone.
A biphasic trend was again observed, as at the higher concentrations of ZnSO4 (14.38, 28.75
and 143.77 mg mL-1) higher log reductions of 3.01, 2.56 and 2.22 were observed.
Antiviral activity of PRE, punicalagin, ellagic acid and aciclovir against
HSV-1 and aciclovir-resistant HSV-2
In this section, the viral replication inhibitory activities of PRE, punicalagin and ellagic acid
were determined alongside the established topical antiviral drug, aciclovir. Two strains of
Fig 3. Comparison of the virucidal log reduction of HSV-1 by PRE and punicalagin against HSV-1 on a mass-to-mass basis
(n = 4 ± SD). 1: PRE 0.05 mg mL-1; 2. PRE 0.01 mg mL-1; 3. punicalagin 0.05 mg mL-1 (46.1 μM); 4. punicalagin 0.01 mg mL-1 (9.22 μM).
Results show greater potency achieved with equivalent concentrations of punicalagin compared to PRE.
https://doi.org/10.1371/journal.pone.0179291.g003
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Fig 4. Virucidal log reduction due to the main punicalagin versus ellagic acid solubilised in 10% aqueous DMSO
(n = 4 ± SD). Results show no activity of ellagic acid, whereas punicalagin was significantly greater than control.
https://doi.org/10.1371/journal.pone.0179291.g004
Fig 5. Effect of ZnSO4 concentrations on the potentiated virucidal activity of punicalagin (0.01 mg mL-1) (n = 4 ± SD). Results
show a maximum at 1.44 mg mL-1, after which the pattern is unpredictable.
https://doi.org/10.1371/journal.pone.0179291.g005
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Herpes simplex virus were used: HSV-1 and HSV-2 aciclovir resistant (ACR). Table 2 shows
that the EC50 of aciclovir against HSV-1 was 0.81 μM (which is equivalent to 0.182 μg mL-1)
and in general agreement with levels stated in the literature [24,25].
The PRE extract exhibited potent antiviral properties against HSV-1 0.556 ± 0.39 μg mL-1
(concentration range 1, 0.5, 0.01, 0.005 and 0.001 μg mL-1) and on a mass-to-mass basis PRE is
over 1000 times more potent than aciclovir as an antiviral. PRE demonstrated an even greater
antiviral response against the aciclovir-resistant strain HSV-ACR with an EC50 of
0.016 ± 0.009 μg mL-1, whereas aciclovir showed no effect (100 μM). Surprisingly neither
punicalagin nor ellagic acid elicited any antiviral activity at the concentrations tested (IC50
100 μM). This result indicates that, unlike in the earlier tests where punicalagin was clearly
involved in virucidal activity, the antiviral activity of PRE cannot be attributed to this com-
pound. Thus antiviral activity is due to another phytochemical constituent of PRE or, more
likely, a combination of constituents. The addition of ZnSO4 was not found to increase the
anti-replicative potential of the extracts.
Antiviral profiles for PRE vs HSV-1, PRE vs HSV-2 ACR, PRE + ZnSO4 vs HSV-1 and aci-
clovir vs HSV-1 are displayed in Fig 6. It is interesting to note the shape of these graphs—the
sharp decline in viral activity over a small concentration gradient implies that PRE ± ZnSO4
requires a threshold concentration to have any antiviral effect. The shape of the EC50 curve for
aciclovir exhibits a gradual decline in antiviral activity over a wide concentration range—this
and the antiviral activity of against HSV-2 ACR which is resistant to aciclovir suggests that the
antiviral activity of PRE is exercised by a different mode of action to that of aciclovir. Synergis-
tic inhibition of ACV-resistant HSV replication was reported using a combination of the ella-
gitannins: castalagin, vescalagin and grandinin—no mechanism was proposed, although the
work did demonstrate the absence of toxic effects [26].
Cytotoxicity
Cytotoxicity was determined using a widely-used MTS cell proliferation assay. Fig 7 shows the
percentage of viable cells after application of PRE 0.1 mg mL-1, ZnSO4 0.1 M and phthalate
buffer pH 4.5, alone and in combination. Each formulation was made in the phthalate buffer at
pH 4.5. There was no significant difference (p>0.05) between the applied formulations at any
time point over the 72 h period resulting in no decrease in the percentage of viable cells in
comparison to the control. Thus, no cytotoxic effect was observed on the application of PRE
Table 2. The antiviral IC50 against Herpes simplex virus-1 (HSV-1) and acyclovir-resistant Herpes simplex virus (HSV-ACR) of PRE, punicalagin,
ZnSO4 and ellagic acid in comparison to aciclovir (n = 3 ± SD). Note: IC50 concentration of PRE is in units of mass mL-1 rather than μM as it is a complex
mixture of compounds.
Challenge MW Virus IC50 (μg mL-1) IC50 (μM)
PRE + ZnSO4 N/A HSV-1 0.550 ± 0.062 N/A
PRE N/A HSV-1 0.560 ± 0.039 N/A
HSV-ACR 0.016 ± 0.009 N/A
Punicalagin 1084.7 HSV-1 108.47 100
HSV-ACR 108.47 100
Ellagic acid 302.2 HSV-1 30.22 100
HSV-ACR 30.22 100
ZnSO4 161.47 HSV-1 16.15 100
HSV-ACR 16.15 100
Aciclovir 225.21 HSV-1 0.182 0.81 ± 0.03
HSV-ACR 22.52 100
https://doi.org/10.1371/journal.pone.0179291.t002
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and ZnSO4 at any concentration used in this work. This is consistent with previous work using
a combination of ellagitannins [26]. However, the results for ZnSO4 are not in line with earlier
work which, based upon the monitoring of DNA synthesis kinetics, predicts cytotoxicity at
the levels used in the current work [27]. The Vero (green monkey kidney epithelial) cells
(ATCC-CCL81) used in the current work and the African green monkey kidney (AGMK) cell
line RC 37 Rita (Italdiagnostics) used by Kumel, are different isolations of the same cell type;
both epithelial, so should have similar virucide penetration properties; however, much shorter
incubations times were used in the current work.
General discussion
The mechanism for the potentiated virucidal activity is currently under investigation, with the
formation of a Zn-tannin complex being likely involved. Clearly the biphasic concentration-
dependant behaviour to ZnSO4 of both PRE and punicalagin (Figs 2 and 5) is surprising and
counter-intuitive, although each experiment was performed four times. Potentiation increased
up to 1.44 mg mL-1, after which it decreased before again reaching a maximum, thereafter
steadily diminishing. PRE is a complex mixture of phytochemicals and the addition of ZnSO4
adds to the complex interplay between constituents, in solution and at the virus surface. Zinc
(II) ions are known to be active against HSV [28,29] and limited activity was confirmed in Fig
1. Kumel et al published an in depth study on the inactivation of free HSV by zinc sulphate,
and differences may be explained by extended exposure periods in comparison to the current
work [27], also the different strains used may have had different sensitivities to zinc [28]. It
was shown that punicalagin targeted and inactivated HSV-1 viral particles and could prevent
binding, penetration, and cell-to-cell spread [10]. One explanation could therefore be that at
higher levels of zinc (which has less potency than PRE+Zn), complexes could form between
zinc and other phytochemicals and block the punicalagin/zinc challenge at the HSV surface.
Fig 6. Antiviral EC50 curves covering the range 0.001, 0.005, 0.01, 0.5, 1 μg mL-1 (n = 3 ± SD).
https://doi.org/10.1371/journal.pone.0179291.g006
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Alternatively, it is feasible that similarities between the virucidal effects of the higher con-
centrations of ZnSO4 combined with PRE and punicalagin can be observed and may indicate
that a dual effect is occurring. It is possible that the viral envelope is first compromised by the
punicalagin and then bound by the free Zn2+ ions, however, at higher concentrations of
ZnSO4, the Zn
2+ ions may act first allowing for the punicalagin to then combine with the pro-
tein envelope thus destroying it. A similar level of viral destruction is observed within the PRE
+ ZnSO4 system, however, due to the protective nature of a natural product upon its constitu-
ent parts, the virucidal activity of punicalagin remains active and thus potentiation is main-
tained over a greater concentration range of ZnSO4 addition (0.14 and 28.75 mg mL
-1). A
decrease in virucidal activity at ZnSO4 concentrations 0.29, 0.144 and 0.288 mg mL
-1 to puni-
calagin and 2.88 to PRE may indicate competition for a specific protein and or binding site,
hindering potentiation. The virucidal mode of action of pomegranate polyphenols has yet to
be elucidated, however other research has shown the interaction between polyphenols with
envelope viral glycol proteins of influenza [7, 30].
Examination of a range of zinc salts showed that comparable potentiation was achieved to
ZnSO4 when equal concentrations were employed and the counterion had no adverse effect
on the host Vero cells. This is strong evidence that the Zn (II) ion in solution is principally
responsible for the potentiating effect. It is interesting to note the comparability of antiviral
activity between PRE and the established antiviral aciclovir (Table 2). Even more interesting is
the fact that PRE demonstrated an even greater activity against ACR-HSV–the implication is
that PRE could have a role in future HSV strategies, when aciclovir approaches the end of its
therapeutic lifetime. The addition of ZnSO4 was found not to provide enhanced activity and
therefore is not involved in a potentiating mechanism during the viral replication stage.
In the current work the Vero host cells were not adversely affected by either PRE or punica-
lagin, supporting the previous work by Lin et al [10]. Administration of a pomegranate fruit
extract, standardized to 30% punicalagins, to Wistar rats showed no adverse effect as high as
Fig 7. Cell Titre 96 AQueous assay cytotoxic evaluation: the percentage of viable cells remaining after
application of total pomegranate tannins (purple), tannin free fraction (light blue), pomegranate rind
extract (PRE) 0.1 mg mL-1 (dark blue), ZnSO4 0.1 M (red) and PRE 0.1 mg mL-1 + ZnSO4 0.1 M (green)
after 6, 24, 48 and 72 h (n = 3 ± SD). There was no statistical difference in viable cell count across the
duration of the experiments, indicating absence of cytotoxicity with any of the solutions tested.
https://doi.org/10.1371/journal.pone.0179291.g007
Pomegranate potentiation by zinc
PLOS ONE | https://doi.org/10.1371/journal.pone.0179291 June 30, 2017 12 / 15
600 mg/kg body weight/day [31]. Although a hydroalcoholic pomegranate whole fruit extract
at oral doses greater than 70 mg/kg body weight were found to be potentially toxic [32]. In the
current work, the extract (with and without ZnSO4) was applied locally to the skin and at
doses significantly below those used in these earlier papers, further indicating safety for topical
use. Indeed, any cytotoxic effects, if they occurred, would be expected to elicit an inflammatory
response. In contrast, the anti-inflammatory properties of pomegranate extracts are well docu-
mented [33] and our previous work has demonstrated downregulation of COX-2 levels in ex
vivo skin, following the penetration of PRE and ZnSO4 through epidermis and mucous mem-
branes [34,35]. Overall, the absence of cytotoxic effects and demonstrable anti-inflammatory
activity suggests the safe application of PRE and zinc ions to skin in vivo.
Together with the current antiviral and virucidal data against HSV and aciclovir-resistant
HSV, the co-administration of PRE or punicalagin has potential as a novel multi-functional
topical therapeutic for coldsores; there is also potential in the treatment of anogenital herpes
and viral keratitis. By extrapolation, the topical application of PRE and ZnSO4 might be
expected to result in virucidal kill outside of the host cell post-budding and help eliminate the
viral vesicles. This would have important beneficial consequences for preventing viral transfer
by a number of routes, eg human mouth-to-mouth. Additionally, PRE would inhibit viral
replication within adjacent cells preventing formation of a viral cluster, which in turn would
prevent a cold sore outbreak. Finally, an additional advantage of the proposed therapeutic
combination is that the virucidal action involves a potentiated interaction between zinc ions
and the complex mixture of phytochemicals, and such potentiation is believed to inhibit
microbial resistance by making microbial adaptability very difficult [36,37].
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